Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
01 February 2018Website:
http://www.sol-gel.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:09:21 GMTDividend
Analysts recommendations
Institutional Ownership
SLGL Latest News
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.
NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company specializing in treatments for severe skin conditions, is currently conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome. In addition to their two approved large-category dermatology products, TWYNEO® and EPSOLAY®, Sol-Gel announced today that they have entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. Ltd. in China for the commercialization of TWYNEO for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.
What type of business is Sol-Gel Technologies?
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
What sector is Sol-Gel Technologies in?
Sol-Gel Technologies is in the Healthcare sector
What industry is Sol-Gel Technologies in?
Sol-Gel Technologies is in the Biotechnology industry
What country is Sol-Gel Technologies from?
Sol-Gel Technologies is headquartered in Israel
When did Sol-Gel Technologies go public?
Sol-Gel Technologies initial public offering (IPO) was on 01 February 2018
What is Sol-Gel Technologies website?
https://www.sol-gel.com
Is Sol-Gel Technologies in the S&P 500?
No, Sol-Gel Technologies is not included in the S&P 500 index
Is Sol-Gel Technologies in the NASDAQ 100?
No, Sol-Gel Technologies is not included in the NASDAQ 100 index
Is Sol-Gel Technologies in the Dow Jones?
No, Sol-Gel Technologies is not included in the Dow Jones index
When does Sol-Gel Technologies report earnings?
The next expected earnings date for Sol-Gel Technologies is 09 August 2024